NCT06763965 2026-03-23
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1/2 Enrolling by invitation
Clinical Trials
13 trialsNCT02705196 2026-02-24
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
Phase 1/2 Completed
NCT02048332 2025-12-16
VSTs
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Recruiting
NCT05271318 2025-11-03
PROTA
TILT Biotherapeutics Ltd.
Phase 1/2 Recruiting
NCT06909110 2025-08-14
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Stanford University
Phase 1/2 Recruiting
NCT06027879 2025-06-25
Gamma Capture
University of Pittsburgh
Phase 1/2 Enrolling by invitation
NCT03475212 2025-05-11
ACES
Pediatric Transplantation & Cellular Therapy Consortium
Phase 1/2 Active not recruiting
NCT03754933 2025-03-27
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
GeoVax, Inc.
Phase 1/2 Completed
NCT04097002 2023-10-31
First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.
Orca Therapeutics B.V.
Phase 1/2 Unknown
NCT03159364 2019-09-19
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT01570283 2019-05-30
ARMS
AlloVir
Phase 1/2 Completed
NCT02844699 2017-09-20
A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer
Panacela Labs LLC
Phase 1/2 Unknown
NCT00711035 2016-04-26
CHALLAH
Baylor College of Medicine
Phase 1/2 Completed